Menopause and hot flushes
BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.
Menopause after age 45 (clinical diagnosis)
Laboratory tests
- No laboratory test is needed for diagnosis after 45 years.
- FSH (only between 40 and 45 years, with symptoms and altered cycles)if needednon-French guidelineWoman aged 40 to 45 years with suggestive symptoms, including a change in cycles, without combined oestrogen-progestogen contraception or high-dose progestogen [2].
Do not order
- FSH, oestradiol, AMH, inhibins (and follicle count or ovarian volume on ultrasound) to diagnose menopause after 45 years: NICE recommends not using them [2]; the French clinical practice guideline (RPC) indicates no hormone measurement or imaging in the typical situation [3]: no further assessment is needed (grade A) [4].
- FSH on a combined oestrogen-progestogen pill or high-dose progestogen: uninterpretable for the diagnosis of menopause [2,3].
Suspected premature ovarian insufficiency (before age 40)
Laboratory tests
- Serum β-hCG
- FSH
- Oestradiol
- TSH
- AMH (if FSH is inconclusive)if needednon-French guidelineFSH borderline or discordant with the clinical picture: AMH can help to confirm the diagnosis, but is not a first-line test [1].
4 to 6 weeks later
- FSH (second measurement)if needednon-French guidelineNICE requires two raised FSH results 4 to 6 weeks apart [2]; ESHRE 2024 is satisfied with a single FSH > 25 IU/L if the picture is typical and repeats it only in case of doubt [1].
Once POI is confirmed (excluding iatrogenic cause), after information and consent
- Karyotype
- FMR1 premutation testing (fragile X)
- Anti-21-hydroxylase antibodies (anti-adrenal), if the cause remains unknown
- Lipid profile
- Fasting plasma glucose
Do not order
Before menopausal hormone therapy
Fasting laboratory tests (if not recent)
- Lipid profile (if no recent tests)if neededTo assess the level of cardiovascular risk before HRT, taking into account the classic risk factors, including dyslipidaemia [4,8]; pointless if a recent test is available.
- Fasting plasma glucose (if no recent tests)if neededSame aim: document the classic cardiovascular risk factors before HRT, including diabetes [4,8].
Do not order
- Serum oestradiol to monitor the bone effect of HRT: not recommended (grade B) [4].
Atypical hot flushes
Laboratory tests
- TSH
- 24-hour urinary metanephrines (metanephrine and normetanephrine) with urinary creatinineif neededHypertension with palpitations, sweating or headaches [12], or flushes associated with hypertensive surges [13].
- 24-hour urinary 5-HIAAif needednon-French guidelineFlushes without sweating, with diarrhoea or other digestive signs, wheezing: look for a serotonin-secreting neuroendocrine tumour [14].
- Serum tryptaseif needednon-French guidelineFlushes with pruritus, urticaria, malaise or hypotension: mastocytosis [14].
Do not order
Sources (15)
- ESHRE, ASRM, CREWHIRL and IMS Guideline Group on POI; Panay N, Anderson RA, Bennie A, et al. Evidence-based guideline: premature ovarian insufficiency. Hum Reprod Open. 2024;2024(4):hoae065.
- National Institute for Health and Care Excellence. Menopause: identification and management. NICE guideline NG23, publiée le 12 novembre 2015, dernière mise à jour le 15 avril 2026 (recommandations 1.3 et 1.7).
- Rousset-Jablonski C. Comment diagnostiquer la ménopause ? Prise en charge de la femme ménopausée : recommandations pour la pratique clinique du CNGOF et du GEMVi. Gynecol Obstet Fertil Senol. 2021;49(5):318-328.
- Trémollieres FA, Chabbert-Buffet N, Plu-Bureau G, Rousset-Jablonski C, Lecerf JM, Duclos M, et al. Management of postmenopausal women: Collège National des Gynécologues et Obstétriciens Français (CNGOF) and Groupe d'Etude sur la Ménopause et le Vieillissement (GEMVi) Clinical Practice Guidelines. Maturitas. 2022;163:62-81.
- European Menopause and Andropause Society (EMAS). Menopause Essentials: Diagnostic tests for menopause. 2022.
- Australasian Menopause Society (AMS). Information Sheet: Diagnosing menopause. 12 mai 2022.
- Nederlandse Vereniging voor Obstetrie en Gynaecologie (NVOG) et al. Richtlijn CVRM na een reproductieve aandoening, module « CVRM na primair ovariële insufficiëntie », 29 avril 2015, validité évaluée le 2 mars 2023 (Pays-Bas).
- Plu-Bureau G, Mounier-Vehier C. Traitement hormonal de la ménopause et risque cardiovasculaire. Prise en charge de la femme ménopausée : recommandations pour la pratique clinique du CNGOF et du GEMVi. Gynecol Obstet Fertil Senol. 2021;49(5):438-447.
- Hugon-Rodin J, Perol S, Plu-Bureau G. Ménopause et risque thromboembolique veineux. Prise en charge de la femme ménopausée : recommandations pour la pratique clinique du CNGOF et du GEMVi. Gynecol Obstet Fertil Senol. 2021;49(5):455-461.
- Bass M, Kasper RE. Menopause Management: When Hormone Therapy Is Appropriate. Am Fam Physician. 2026;113(2):115-117.
- US Preventive Services Task Force, Mangione CM, et al. Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement. JAMA. 2022;328(17):1740-1746.
- Centre de référence des maladies rares des surrénales. Protocole national de diagnostic et de soins (PNDS) : Phéochromocytomes et paragangliomes. Synthèse à destination du médecin traitant, 30 septembre 2021 (publiée par la HAS).
- Maitrot-Mantelet L, Perol S, Plu-Bureau G. Diagnostics différentiels des bouffées vasomotrices. Prise en charge de la femme ménopausée : recommandations pour la pratique clinique du CNGOF et du GEMVi. Gynecol Obstet Fertil Senol. 2021;49(5):329-334.
- García-Sáenz MR, Sosa-Eroza E, Ferreira-Hermosillo A, et al. Flushing: neuroendocrine mechanisms and a structured diagnostic approach. Clin Endocrinol (Oxf). 2026;105(4):367-377.
- Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 4050 (X fragile), 1489 (autoanticorps antisurrénale), 0466 (5-HIAA urinaire), 0477 (métanéphrines urinaires), 0969 (tryptase).